ArticleVeterinary world2026
Synergistic apoptotic and epithelial-mesenchymal transition-inhibitory effects of
Article in Veterinary world, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Canine mammary cancer (CMC) is one of the most common malignant neoplasms in female dogs, with high metastatic potential and limited therapeutic options. Natural bioactive compounds derived from medicinal mushrooms have gained increasing attention because of their anticancer properties and low toxicity. Materials and Methods: The anticancer activity of HE methanolic extract was evaluated using CHMp-13a and CHMp-5b CMC cell lines, while Madin-Darby canine kidney cells were used as normal controls. Cell viability was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Cell migration and invasion were evaluated using wound healing and Transwell assays, respectively. Apoptosis was analyzed using Annexin V-fluorescein isothiocyanate/propidium iodide flow cytometry. Relative mRNA and protein expression levels of apoptosis- and EMT-related markers were determined using quantitative real-time polymerase chain reaction and western blotting. The phytochemical profile of the extract was characterized using liquid chromatography quadrupole time-of-flight mass spectrometry. Results: HE extract significantly inhibited proliferation of both CMC cell lines in a dose- and time-dependent manner, with greater selectivity toward CHMp-13a cells and minimal cytotoxicity in normal cells. Morphological analysis revealed apoptotic features, including cell shrinkage, detachment, and cytoplasmic vacuolization. The extract significantly suppressed migration and invasion capacities of both CMC cell lines. Flow cytometric analysis demonstrated increased apoptotic cell populations following treatment. Molecular analyses showed upregulation of the pro-apoptotic marker BAX and downregulation of the anti-apoptotic marker BCL-2. Furthermore, HE extract suppressed EMT progression by increasing E-cadherin expression while reducing N-cadherin expression. Phytochemical screening identified 17 bioactive compounds, including erinacines, hericenones, hericene derivatives, and phenolic compounds, which may contribute to the observed anticancer activities. Conclusion: HE extract demonstrated potent
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.